vs
Side-by-side financial comparison of Sensus Healthcare, Inc. (SRTS) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.
cbdMD, Inc. is the larger business by last-quarter revenue ($5.0M vs $4.9M, roughly 1.0× Sensus Healthcare, Inc.). cbdMD, Inc. runs the higher net margin — -5.6% vs -64.1%, a 58.5% gap on every dollar of revenue. On growth, cbdMD, Inc. posted the faster year-over-year revenue change (-1.9% vs -62.2%). cbdMD, Inc. produced more free cash flow last quarter ($-977.3K vs $-2.4M). Over the past eight quarters, cbdMD, Inc.'s revenue compounded faster (7.1% CAGR vs -31.9%).
Sensus Healthcare, Inc. is a medical technology company that designs, manufactures and commercializes innovative non-invasive superficial radiation therapy systems. Its products are primarily used for treating non-melanoma skin cancers, keloids, and select cosmetic dermatology conditions, serving healthcare providers and clinical facilities worldwide.
cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.
SRTS vs YCBD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.9M | $5.0M |
| Net Profit | $-3.2M | $-283.1K |
| Gross Margin | 38.4% | 59.8% |
| Operating Margin | -63.8% | -5.7% |
| Net Margin | -64.1% | -5.6% |
| Revenue YoY | -62.2% | -1.9% |
| Net Profit YoY | -304.9% | -1975.7% |
| EPS (diluted) | $-0.19 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.9M | $5.0M | ||
| Q3 25 | $6.9M | $4.7M | ||
| Q2 25 | $7.3M | $4.6M | ||
| Q1 25 | $8.3M | $4.7M | ||
| Q4 24 | $13.1M | $5.1M | ||
| Q3 24 | $8.8M | $4.6M | ||
| Q2 24 | $9.2M | $5.2M | ||
| Q1 24 | $10.7M | $4.4M |
| Q4 25 | $-3.2M | $-283.1K | ||
| Q3 25 | $-943.0K | $-680.0K | ||
| Q2 25 | $-1.0M | $-895.3K | ||
| Q1 25 | $-2.6M | $-480.8K | ||
| Q4 24 | $1.5M | $15.1K | ||
| Q3 24 | $1.2M | $-152.8K | ||
| Q2 24 | $1.6M | $459.7K | ||
| Q1 24 | $2.3M | $-3.0M |
| Q4 25 | 38.4% | 59.8% | ||
| Q3 25 | 39.4% | 58.8% | ||
| Q2 25 | 39.7% | 61.5% | ||
| Q1 25 | 52.2% | 62.3% | ||
| Q4 24 | 54.4% | 66.5% | ||
| Q3 24 | 59.3% | 53.9% | ||
| Q2 24 | 58.7% | 65.8% | ||
| Q1 24 | 62.5% | 59.0% |
| Q4 25 | -63.8% | -5.7% | ||
| Q3 25 | -37.3% | -14.5% | ||
| Q2 25 | -26.6% | -19.6% | ||
| Q1 25 | -31.7% | -10.2% | ||
| Q4 24 | 13.2% | -1.7% | ||
| Q3 24 | 16.9% | -6.9% | ||
| Q2 24 | 21.5% | -7.4% | ||
| Q1 24 | 27.1% | -35.4% |
| Q4 25 | -64.1% | -5.6% | ||
| Q3 25 | -13.7% | -14.4% | ||
| Q2 25 | -14.2% | -19.4% | ||
| Q1 25 | -30.8% | -10.1% | ||
| Q4 24 | 11.8% | 0.3% | ||
| Q3 24 | 13.7% | -3.4% | ||
| Q2 24 | 17.4% | 8.9% | ||
| Q1 24 | 21.3% | -68.8% |
| Q4 25 | $-0.19 | — | ||
| Q3 25 | $-0.06 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.16 | — | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $0.07 | — | ||
| Q2 24 | $0.10 | $-0.15 | ||
| Q1 24 | $0.14 | $-1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.1M | $3.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.1M | $9.0M |
| Total Assets | $53.0M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.1M | $3.4M | ||
| Q3 25 | $24.5M | $2.3M | ||
| Q2 25 | $22.2M | $1.1M | ||
| Q1 25 | $19.1M | $1.8M | ||
| Q4 24 | $22.1M | $2.0M | ||
| Q3 24 | $22.6M | $2.5M | ||
| Q2 24 | $19.0M | $2.4M | ||
| Q1 24 | $14.7M | $2.1M |
| Q4 25 | $48.1M | $9.0M | ||
| Q3 25 | $51.2M | $7.2M | ||
| Q2 25 | $52.1M | $6.1M | ||
| Q1 25 | $53.0M | $665.8K | ||
| Q4 24 | $55.8M | $1.8M | ||
| Q3 24 | $54.1M | $2.0M | ||
| Q2 24 | $52.9M | $3.0M | ||
| Q1 24 | $51.2M | $3.1M |
| Q4 25 | $53.0M | $11.8M | ||
| Q3 25 | $58.3M | $10.4M | ||
| Q2 25 | $58.9M | $9.9M | ||
| Q1 25 | $60.2M | $10.9M | ||
| Q4 24 | $62.2M | $11.5M | ||
| Q3 24 | $59.9M | $10.6M | ||
| Q2 24 | $58.2M | $13.8M | ||
| Q1 24 | $57.3M | $14.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.2M | $-812.5K |
| Free Cash FlowOCF − Capex | $-2.4M | $-977.3K |
| FCF MarginFCF / Revenue | -47.9% | -19.5% |
| Capex IntensityCapex / Revenue | 3.2% | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $332.0K | $-2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.2M | $-812.5K | ||
| Q3 25 | $2.3M | $-240.7K | ||
| Q2 25 | $3.1M | $-704.2K | ||
| Q1 25 | $-2.7M | $-189.5K | ||
| Q4 24 | $-827.0K | $-317.9K | ||
| Q3 24 | $4.0M | $167.4K | ||
| Q2 24 | $4.2M | $289.8K | ||
| Q1 24 | $-8.2M | $-704.1K |
| Q4 25 | $-2.4M | $-977.3K | ||
| Q3 25 | $2.3M | $-243.6K | ||
| Q2 25 | $3.1M | $-705.7K | ||
| Q1 25 | $-2.7M | $-205.0K | ||
| Q4 24 | $-1.1M | $-482.3K | ||
| Q3 24 | $3.6M | $157.4K | ||
| Q2 24 | $4.2M | — | ||
| Q1 24 | $-8.4M | $-708.7K |
| Q4 25 | -47.9% | -19.5% | ||
| Q3 25 | 33.3% | -5.2% | ||
| Q2 25 | 42.2% | -15.3% | ||
| Q1 25 | -32.2% | -4.3% | ||
| Q4 24 | -8.6% | -9.4% | ||
| Q3 24 | 40.9% | 3.5% | ||
| Q2 24 | 45.8% | — | ||
| Q1 24 | -79.0% | -16.2% |
| Q4 25 | 3.2% | 3.3% | ||
| Q3 25 | 0.1% | 0.1% | ||
| Q2 25 | 0.4% | 0.0% | ||
| Q1 25 | 0.1% | 0.3% | ||
| Q4 24 | 2.3% | 3.2% | ||
| Q3 24 | 3.8% | 0.2% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 2.2% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.53× | -21.06× | ||
| Q3 24 | 3.25× | — | ||
| Q2 24 | 2.62× | 0.63× | ||
| Q1 24 | -3.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SRTS
| Products | $2.8M | 57% |
| Other | $2.1M | 43% |
YCBD
| Sales Channel Directly To Consumer | $3.6M | 72% |
| Sales Channel Through Intermediary | $1.4M | 28% |
